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Abstract
In diabetic patients, vascular disease and autonomic dysfunction might compromise cerebral autoregulation and contribute to orthostatic
intolerance. The aim of our study was to determine whether impaired cerebral autoregulation contributes to orthostatic intolerance during
lower body negative pressure in diabetic patients.
Thirteen patients with early-stage type 2 diabetes were studied. We continuously recorded RR-interval, mean blood pressure and mean
middle cerebral artery blood flow velocity at rest and during lower body negative pressure applied at −20 and −40 mm Hg. Spectral powers
of RR-interval, blood pressure and cerebral blood flow velocity were analyzed in the sympathetically mediated low (LF: 0.04–0.15 Hz) and
the high (HF: 0.15–0.5 Hz) frequency ranges. Cerebral autoregulation was assessed from the transfer function gain and phase shift between
LF oscillations of blood pressure and cerebral blood flow velocity. In the diabetic patients, lower body negative pressure decreased the RR-
interval, i.e. increased heart rate, while blood pressure and cerebral blood flow velocity decreased. Transfer function gain and phase shift
remained stable.
Lower body negative pressure did not induce the normal increase in sympathetically mediated LF-powers of blood pressure and cerebral
blood flow velocity in our patients indicating sympathetic dysfunction. The stable phase shift, however, suggests intact cerebral
autoregulation. The dying back pathology in diabetic neuropathy may explain an earlier and greater impairment of peripheral vasomotor than
cerebrovascular control, thus maintaining cerebral blood flow constant and protecting patients from symptoms of presyncope.
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1. Introduction
Autonomic dysfunction is an important complication of
diabetes mellitus. Up to 90% of diabetic patients experience
autonomic-related symptoms such as impaired sweating as
well as pupillary, gastrointestinal, genitourinary or cardio-
vascular symptoms [1,2]. Cardiovascular autonomic neurop-
athy is an important complication of diabetes because it is
associated with increased risks of morbidity and mortality
[3]. In a previous study we demonstrated that the autonomic
regulation of the heart and blood vessels is impaired in
patients with type 2 diabetes mellitus [4]. One manifestation
of cardiovascular autonomic neuropathy in diabetic patients
is orthostatic intolerance [2]. Typical symptoms of orthostatic
intolerance include postural dizziness, blurred vision, neck
pain or even syncope [2]. Orthostatic intolerance in patients
with autonomic failure is related to an inadequate vascular
resistance response to the upright posture with a subsequent
drop in blood pressure [5]. There is, however, evidence that
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impaired regulation of the cerebral blood vessels might also
contribute to orthostatic intolerance in some patients [6].
Cerebral autoregulation refers to the intrinsic ability of the
cerebral blood vessels to maintain a near-constant cerebral
blood flow despite changes in perfusion pressure, provided
the blood pressure remains within certain limits (50–150 mm
Hg). Several mechanisms are thought to contribute to cere-
bral autoregulation. These include myogenic, endothelial and
neurogenic influences [7–9]. Diabetic patients have been
shown to have endothelial dysfunction and other microvas-
cular abnormalities [10]. It is therefore possible that in addi-
tion to dysfunctional autonomic regulation of the blood
vessels, diabetic patients have impaired cerebral autoregulation.
The aim of this study was to investigate the autonomic and
vascular responses to orthostatic stress in patients with type 2
diabetes mellitus. Orthostatic stress was simulated by ap-
plication of lower body negative pressure (LBNP). In healthy
individuals LBNP causes pooling of blood in the veins of the
lower body and decreases cardiac output [11,12]. Blood pres-
sure is maintained near-constant during LBNP by symphate-
tically mediated peripheral vasoconstriction, and there is little
change in cerebral blood flow [11]. We hypothesized that
patients with diabetesmellitus would have impaired regulation
of the peripheral and cerebral blood vessels and that this might
contribute to orthostatic intolerance in these patients.
2. Materials and methods
2.1. Subjects
Thirteen patients (4 women, 9 men) with diabetes mellitus
type 2 were investigated. Their mean age was 58±6 years,
their height was 171±9 cm, their weight was 84±19 kg and
the mean duration of diabetes 85±55 months.
All patients had been diagnosed with type 2 diabetes
according to the internationally accepted recommendations
based on the criteria of the AmericanDiabetes Association and
the World Health Organization (WHO) [13]. All our patients
performed glycemic control. Five patients were treated with
insulin and 8 patients were on oral antidiabetics such as sul-
fonylureas or metformin.
All participants were tested in the morning between 8 and
12 a.m. after an overnight fast of at least 8 h. The diabetic
patients had taken their last subcutaneous insulin injection or
oral antidiabetic medication before bedtime and did not take
their morning dose on the day of the study. They were
instructed to avoid hypoglycemia at the day of the testing and
to eat a light snack containing a cereal bar and a glass of milk
if they experienced either symptoms of hypoglycemia or if
their morning glucose level was below 70 mg/dl. To assure
the absence of hypoglycemia within 24 h prior to testing, all
patients self-monitored their blood glucose at least three
times 1 h after meals and reported a postprandial glucose level
below 140 mg/dl. To ensure long-term glycemic control, we
only included patients in our study who had normal or near-
normal HbA1c levels.
None of the diabetic patients showed any symptoms or
signs of diabetic somatic neuropathy. One patient occasion-
ally suffered from symptoms of orthostatic intolerance such
as postural dizziness or blurred vision. One other patient had
a history of diabetic retinopathy. The clinical characteristics
of the patients are summarized in Table 1.
We also tested 15 age- and sex-matched healthy controls
(5 women, 10 men). Their mean age was 59±9 years, their
height was 171±9 cm and their weight was 76±16 kg. The
controls were recruited among healthy friends or relatives of
staff members and patients.
The study was approved by the local ethics committee of
the University of Erlangen-Nuremberg and written informed
consent was obtained according to the declaration of Helsinki.
None of the participants had a history of an acute illness,
chronic alcohol abuse, carcinoma of any origin, myopathy,
hyper- or hypothyroidism, arterial hypertension, atheroscle-
rosis, previous kidney or pancreas transplantation, signifi-
cant hepatic or renal disease or any other condition that
would interfere with the patient's ability to participate in the
study. None of the participants was on any antihypertensive
or other medication known to influence the cardiovascular or
Table 1
Clinical characteristics and data on diabetes control including blood glucose level reported by the patients, HbA1c, antidiabetic medication, systolic and diastolic
blood pressure and diabetic complications
Patient's ID HbA1c [%] Glucose level [mg/dl] Antidiabetic medication Complications Systolic BP [mm Hg] Diastolic BP [mm Hg]
1 7.2 107 Metformin None 132 78
2 7.4 103 Metformin Retinopathy 141 79
3 6.9 98 Metformin None 128 80
4 6.7 97 Metformin None 123 76
5 7.5 92 Insulin Presyncope 115 83
6 7.3 111 Insulin None 157 60
7 6.9 115 Insulin None 128 74
8 7.7 105 Glimepiride None 141 87
9 7.5 99 Metformin None 133 45
10 7.2 117 Insulin None 125 67
11 6.8 101 Metformin, glibenclamide None 119 51
12 6.5 106 Glimepiride, metformin None 114 62











autonomic systems. Only three of the 13 patients were reg-
ularly taking lipid-lowering agents such as statins. However,
these 3 patients were instructed to discontinue their medi-
cation for 18 h prior to the study. All participants were asked
to refrain from nicotine, caffeine or alcohol 24 h prior to the
study.
2.2. Procedures
Studies were performed in a quiet room with an ambient
temperature of 24 °C and stable humidity. As hypo- and
hyperglycemia might influence cardiovascular autonomic
modulation, we only tested patients with overall good
glycemic control, in whom the blood glucose level was
within the normal range.
Before the testing procedure, each control and patient
underwent Duplex sonographic examination of the extracra-
nial arteries to rule out atherosclerosis and significant ste-
noses of the carotid arteries.
Following a period for cardiovascular stabilization,
autonomic function was assessed by a standardized battery
of heart rate variability (HRV) tests. This was followed by
application of the LBNP protocol.
2.2.1. Autonomic function testing
Four tests of heart rate variability were performed and
evaluated according to standard criteria: recording at rest,
metronomic breathing, Valsalva maneuver and active stand-
ing up. Before each challenge maneuver an adequate period
at supine rest was guaranteed to assure that heart rate (HR)
had returned to baseline values. Electrocardiogram (ECG)
signals were recorded, transferred to a personal computer via
an analogue–digital converter and analyzed offline using an
automatic program package (ProSciCard, MediSyst, Linden,
Germany).
For HR analysis at rest, respiration was maintained at a
frequency of 12 cycles per min (0.2 Hz) to rule out any bias
due to individual differences in respiration. HRV at rest was
determined by calculating the mean HR, the coefficient of
variation (CV) and the root mean square of successive dif-
ferences (RMSSD) from 170 successive intervals of ECG R
waves. To assess sympathetic and parasympathetic influ-
ences on HR modulation, we performed a fast Fourier trans-
formation of the HR time series recorded over 5 min. The
magnitude of HRmodulation was derived from the powers of
the frequency spectra in the low-frequency (LF: 0.04–
0.15 Hz) and high-frequency (HF: 0.15–0.5 Hz) range. LF
reflects sympathetic and parasympathetic influences and HF
reflects the parasympathetic oscillatory influence of respira-
tory drive on HRV [14]. The powers in the LF and HF ranges
were calculated as the integral under the LF and HF curves
and expressed as bpm2 [15]. Power values below the 2.5th
percentile and above the 97.5th percentile of healthy subjects
were considered abnormal.
To determine HRV during metronomic breathing, a
breathing rhythm of 6 s inspiration and 4 s expiration was
achieved using a bar graph displayed on a computer screen.
For analysis, HR, CVand RMSSD were computed from 100
RR-intervals. In addition, we determined the minimum and
maximum RR-intervals from the breathing cycle with the
greatest difference between the maximum RR-interval dur-
ing expiration and the minimum RR-interval during inspi-
ration. As parameters of HRV, we calculated the difference
between the maximum and minimum RR-intervals (E− I
difference) as well as the ratio of maximum and minimum
RR-intervals (E–I ratio) [16].
The HR response to the Valsalva maneuver was recorded.
We defined the Valsalva ratio as the ratio of the longest RR-
interval during the first 20 s after blowing into a mouthpiece
at a pressure of 40 mmHg with the glottis open for 15 s to the
shortest RR-interval during the strain [17].
The HR response to active standing was assessed by
calculating the ratio between the longest and the shortest RR-
interval within the first 30 s after standing up (the 30:15
ratio) [14].
According to the criteria of Ziegler et al., we diagnosed
cardiac autonomic neuropathy (CAN) if two or more param-
eters of 1.) mean HR, CV and RMSSD at rest, 2.) LF−, HF-
powers at rest, 3.) mean HR, CV, RMSSD, E− I difference
and E–I ratio during metronomic breathing, 4.) the 30:15
ratio and 5.) the Valsalva ratio exceeded age-related normal
control values [16]. Based on the HRV findings, patients were
classified in two subgroups (with or without CAN).
2.2.2. LBNP protocol
Progressive orthostatic stress was elicited by means of
lower body negative pressure (LBNP). Subjects were placed
in a semi-cylindrical chamber that was sealed at the level of
the iliac crests. Pressure within the chamber was indicated by
a manometer and could be lowered using a variable vacuum
source. After a period of at least 40 min of quiet rest, a
baseline period was recorded and LBNP then was applied at
−20 and −40 mm Hg. At each level of LBNP, we allowed at
least 3 min for the biosignals to stabilize, then made re-
cordings during a 3-min period of paced breathing at 0.25 Hz
(15 breaths/min). This breathing frequency ensures that there
is no interference with sympathetically mediated cardiovas-
cular oscillations in the low-frequency (0.04–0.15 Hz) range.
Prior to the start of the procedure, all subjects were trained in
pacing their breathing at 0.25 Hz without hyperventilating
[18].
We made continuous measurements of electrocardiogram
(5-lead ECG) and noninvasive blood pressure (BP) in the
radial artery at the level of the wrist by arterial tonometry
(Colin Pilot™, Colin Medical Instruments Corp., San
Antonio, TX, USA). Respiration wasmonitored by calibrated
electrical inductance plethysmography (Respitrace Calibra-
tor™, Ambulatory Monitoring Inc., Ardsley, NY, USA).
Mean cerebral blood flow velocity (CBFV) of the left
proximal middle cerebral artery (MCA) was assessed by
transcranial Doppler sonography (Multidop XL™, DWL,











insonated at a depth of 35–55 mm using a 2-MHz probe, and
the probe was fixed in place with a headband. Beat-to-beat
values of mean velocity were recorded.
The signals of RR-interval (RRI), blood pressure, res-
piration and cerebral blood flow velocity were digitized at a
sampling rate of 300 Hz, fed to a computer and stored for off-
line analysis. A computer program identified the peak of
each R wave and constructed time series of RR-interval,
systolic, mean and diastolic blood pressure, mean cerebral
blood flow velocities and respiration.
Oscillations in RRI, blood pressure and cerebral blood
flow velocity were characterized by applying power spectral
analysis to these signals using an autoregressive algorithm
[19]. We identified peaks of oscillations in the low- (LF:
0.04–0.15 Hz) and high-frequency ranges (HF: 0.15–
0.50 Hz). As the LF- and HF-powers of RRI may be due to
changes in total power, we normalized the LF- and HF-
powers to more precisely quantify sympathetic and para-
sympathetic cardiac modulation [15,20]. For normalization
of the powers, we calculated the percentage values by
dividing the LF- or HF-powers by the sum of LF- and HF-
powers and multiplying by 100 [21].
Cerebral autoregulation can be considered a high-pass
filter that dampens and shifts slow BP fluctuations but allows
for passing through of rapid oscillations, such as the pulsatile
signals of the BP waves. We performed transfer function
analysis between BP and CBFV oscillations and calculated
the transfer function gain and phase shift in the LF band as
parameters reflecting the quality of dynamic cerebral auto-
regulation. Both parameters were calculated only, if coher-
ence between BP and CBFV was above 0.5, i.e. the two
signals had a stable phase relation for a given frequency of
oscillation and the signals were thought to be synchronized
with each other [20,22,23]. We normalized the transfer func-
tion gain by dividing the LF transfer function gain by the
mean values of the input signal BP and the output signal
CBFV of cerebral autoregulation, i.e. by cerebrovascular
conductance (CBFV/BP) of each patient [24].
2.3. Statistical analysis
All values are presented as mean±standard deviation
(SD). Significance was assumed for P values below 0.05. As
we could not assume a normal distribution, we used the non-
parametric two-sided Friedman test to compare the biosignals
recorded at rest and during negative pressure at −20 and
−40 mm Hg in the healthy volunteers and in the patients. A
commercially available statistical program (SPSS™, SPSS
Inc., Chicago, Ill, USA) was used for data analysis.
3. Results
3.1. Healthy volunteers
None of the healthy volunteers had any pathologic
finding in the heart rate variability tests.
All the healthy volunteers tolerated the LBNP procedure.
In none of the controls, the LBNP protocol had to be ter-
minated due to symptoms of orthostatic intolerance such as
postural dizziness, blurred vision, neck pain or syncope.
The results of the LBNP protocol in the healthy volunteers
are summarized in Table 3.
LBNP increased HR in the controls. BP and CBFV,
however, remained stable during the entire LBNP protocol.
In the controls, LBNP induced a typical decrease in the
parasympathetically mediated HF-power of RRI and a typical
increase in the sympathetically mediated LF-power of BP. In
contrast, LBNP did not influence the sympathetically me-
diated LF-power of CBFV in the healthy volunteers (Fig. 1).
Similarly, both parameters of cerebral autoregulation –
the transfer function gain and phase shift – remained stable
(Fig. 2).
3.2. Diabetic patients
All patients adequately performed the autonomic chal-
lenge maneuvers. Assessment of heart rate at rest, during
metronomic breathing, the Valsalva maneuver and active
standing demonstrated significantly reduced heart rate var-
iability in diabetics. Nine patients (69%) were diagnosed with
cardiac autonomic neuropathy (CAN) according to the
Fig. 1. Influence of lower body negative pressure on the sympathetically
mediated low-frequency powers (LF-powers) of mean blood pressure (BPmean)
(a) and mean cerebral blood flow velocity (CBFVmean) (b) in the 11 orthostase-
tolerant patients and the 15 healthy volunteers. LF-power of BPmean increased
significantly in the controls (Pb0.01), but did not change significantly in the
diabetics during LBNP (PN0.05). LF-power of CBFVmean did not change











criteria suggested by Ziegler et al. Ten of the 13 patients
(77%) had abnormal results during metronomic breathing, 6
patients (46%) had abnormal results during the Valsalva
maneuver and 5 patients (38%) had abnormal results during
active standing (Table 2). In the remaining 4 patients (31%),
heart rate variability was within the normal range. 11 of the 13
diabetics tolerated the entire LBNP protocol. In 2 patients, the
LBNP had to be terminated due to signs of presyncope. Eight
of the 11 orthostatically-tolerant patients had been diagnosed
with CAN.
The results of the LBNP protocol in the diabetic patients
are summarized in Table 4.
As in the controls, LBNP also increased HR and tended to
decrease the HF-power of RRI in the diabetic patients. In
contrast to the controls, BP and CBFV significantly de-
creased during orthostatic challenge. The LF-powers of BP
and CBFV did not change during LBNP (Fig. 1). Similarly,
LBNP did not influence the transfer function gain and phase
shift (Fig. 2; Table 4).
4. Discussion
In response to progressively applied LBNP, our healthy
volunteers maintained stable blood pressure and cerebral
blood flow velocity and showed the expected reflex increase
in heart rate. The power of sympathetically mediated low-
frequency oscillations in mean blood pressure increased in
the healthy subjects during LBNP but with no change in the
power of low-frequency oscillations in cerebral blood flow
velocity. These findings are consistent with previous reports
[18]. In contrast, the diabetic patients showed a slight
reduction in blood pressure and cerebral blood flow velocity
during LBNP. The diabetics also failed to increase the power
of low-frequency oscillations in blood pressure during
LBNP. These results suggest that while type 2 diabetics
have impaired peripheral vascular responses to orthostatic
stress, there is little evidence for impaired cerebral
autoregulation in these patients.
In healthy subjects blood pressure is usually maintained
near-constant during orthostatic stress by arterial baroreflex-
mediated sympathetic vasomotor activation and cardiovagal
withdrawal with a subsequent increase in heart rate [11,20].
The expected increase in the sympathetically mediated low-
frequency power of blood pressure fluctuations was absent
from our diabetic patients and is consistent with our previous
report showing impaired baroreflex-mediated peripheral
vasomotor control in these patients [4]. The blood pressure
reduction that we observed during LBNP in our diabetic
patients was presumably due to an inadequate peripheral
vasoconstrictor response.
Our diabetic patients showed an increase in heart rate
during LBNP that was similar to that observed in the control
subjects. According to our results from the standard heart rate
variability tests, 9 of the 13 patients showed pathologic re-
sults in more than two of the cardiovascular tests including
deep breathing and the Valsalva maneuver, both evaluating
Table 2
Results of the heart rate variability testing in the 15 healthy controls and the
13 patients with diabetes mellitus
Parameter Healthy controls Diabetic patients
At rest
Mean heart rate [bpm] 67.25±12.54 80.49±11.56
CV [%] 3.98±1.32 2.14±0.80




Mean heart rate [bpm] 65.81±11.52 81.22±13.39
CV [%] 5.50±1.89 2.66±1.32
RMSSD [ms] 34.74±14.65 9.72±3.66
E− I-difference [ms] 214.22±89.51 76.33±37.37
E–I ratio 1.26±0.12 1.11±0.07
Valsalva maneuver
Valsalva ratio 1.34±0.20 1.24±0.19
Active standing
30:15 ratio 1.22±0.09 1.13±0.07
(CV: coefficient of variation, RMSSD: root mean square successive
differences, LF: low-frequency, HF: high-frequency).
Fig. 2. Transfer function gain (a) and phase shift (b) between mean blood
pressure (BPmean) and mean cerebral blood flow velocity (CBFVmean)
oscillations in the low-frequency band in 15 healthy volunteers and the 11
orthostase-tolerant patients before and during lower body negative pressure.
Transfer function gain as well as phase shift did not change significantly in










h primarily parasympathetic function [20]. Therefore, onemight expect also a reduced parasympathetic response to
LBNP. While the increase in LF-power of RR-interval might
not necessarily reflect sympathetic activation as the LF-
power indicates both sympathetic and parasympathetic ac-
tivation [15], our diabetic patients showed a decrease in the
parasympathetically mediated normalized HF-power of RR-
interval. Although the decrease in HF-power was not sig-
nificant, there was still a shift towards a more sympathetic
control of heart rate that was sufficient to induce a significant
increase in heart rate during LBNP.
Although CBFV decreased slightly in the diabetic patients
during LBNP, the response was similar to that observed in the
control subjects. This suggests that the responses of the
cerebral blood vessels are intact during orthostatic stress in
diabetics. To evaluate cerebral autoregulation in more detail,
we assessed the ability of the cerebral resistance vessels to
buffer low-frequency blood pressure fluctuations. In the
healthy volunteers, LBNP induced an increase in LF-power
of BP, while the LF-power of CBFV remained stable. This
finding indicates that LBNP-induced increases in LF blood
pressure fluctuations were not transferred onto the cerebro-
vascular system, but were adequately buffered by the cerebral
blood vessels. Since LBNP did not increase the LF-power of
BP in the diabetic patients, it is not possible to determine
whether this aspect of autoregulation is intact. Our results do,
however, show that the application of LBNP did not induce
any substantial increase in cerebral blood flow velocity
fluctuations during orthostatic stress.
In addition to the transfer function gain, the phase relation
between oscillations in BP and CBFV can be also used to
determine the quality of cerebral autoregulation. According
to Diehl et al., a decrease of the phase angle below 60–90°
indicates a more passive behavior of the cerebral vessel bed
and is an indicator of impaired cerebral autoregulation
[20,22,24]. In both our groups, the phase shift remained
stable during LBNP confirming the assumptions of intact
cerebral autoregulation during LBNP.
So far, orthostatic intolerance in patients with autonomic
dysfunction has been primarily linked to impaired blood
pressure regulation or to an abnormal regulation of the
cerebral circulation [6,25]. A recent study in diabetic patients
with a rather long duration of the disease showed cardiac
autonomic neuropathy, orthostatic hypotension and instabil-
ity in cerebral blood flow upon standing, which suggests
impaired cerebral autoregulation [26]. Our patients also have
an impaired sympathetic vasomotor control of peripheral
blood vessels, while cerebral autoregulation still seems to be
intact. In contrast to the study by Mankovsky et al. [26], our
patients had diabetes at a rather early stage of the disease. In
our study, peripheral vasomotor control was evaluated using
blood pressure recordings at the level of the distal radial
artery, while cerebral autoregulation was determined from
transcranial Doppler recordings of the proximal MCA.
Postganglionic sympathetic nerve fibers innervating the
proximal MCA segment originate from the superior cervical
ganglion and are shorter than postganglionic nerve fibers
innervating the distal radial artery at the wrist with their
origin in the stellate ganglion. The dying back pathology in
diabetic neuropathy explains an earlier and greater impair-
ment of peripheral vasomotor control than cerebrovascular
control.
Although our patients had deficient sympathetic vaso-
motor control, higher levels of orthostatic stress did not
induce any symptoms of orthostatic intolerance. Obviously,
cerebral autoregulation still ensured stability in cerebral
blood flow in the presence of sympathetic dysfunction.
Long-term intensive antidiabetic treatment might be useful
not only to avoid future instability of cerebral blood flow
upon standing, but also to prevent for cerebral hypoperfusion
with an increased risk of ischemic strokes.
Table 3
Results of the LBNP protocol obtained in the 15 healthy volunteers






Heart rate [bpm] 62.9±9.0 64.6±8.6 74.3±8.2 Pb0.01
Normalized LF-power
of RRI [%]
42.4±25.1 51.4±24.8 58.7±23.5 Pb0.05
Normalized HF-power
of RRI [%]
76.4±30.0 70.2±27.7 57.4±23.5 Pb0.01
Mean BP [mm Hg] 91.8±12.7 93.8±17.6 92.0±16.9 PN0.05
LF-power of mean BP
[mm Hg2]
1.7±1.3 2.5±1.5 3.9±2.4 Pb0.01
Mean CBFV [cm s−1] 47.4±18.8 42.5±15.1 40.7±13.3 PN0.05
LF-power of mean
CBFV [cm2 s−2]
3.1±3.6 2.8±2.5 4.8±5.6 PN0.05
Transfer function gain
[cm s−1 mm Hg−1]
1.6±1.5 1.2±0.7 1.1±0.6 PN0.05
Phase shift [rad] 1.1±0.5 0.9±0.5 1.3±0.6 PN0.05
Significant differences between parameters at rest and during LBNP are
indicated in bold. (LF: low-frequency, HF: high-frequency, RRI: RR-
interval, BP: blood pressure, CBFV: cerebral blood flow velocity).
Table 4
Results of the LBNP protocol obtained in the 11 patients with diabetes
mellitus, who tolerated the entire LBNP protocol






Heart rate [bpm] 73.4±12.2 76.0±11.5 83.5±10.0 Pb0.01
Normalized LF-power
of RRI [%]
58.7±29.0 68.4±24.0 75.4±16.6 PN0.05
Normalized HF-power
of RRI [%]
41.3±29.0 31.6±24.0 24.6±16.6 PN0.05
Mean BP [mm Hg] 89.8±10.5 93.2±12.2 84.6±14.4 Pb0.05
LF-power of mean BP
[mm Hg2]
2.2±1.9 2.1±2.0 2.1±2.4 PN0.05
Mean CBFV [cm s−1] 40.8±11.6 35.5±13.6 34.2±13.2 Pb0.05
LF-power of mean
CBFV [cm2 s−2]
1.2±1.0 2.0±3.7 2.1±2.9 PN0.05
Transfer function gain
[cm s−1 mm Hg−1]
0.9±0.6 0.9±0.4 0.8±0.4 PN0.05
Phase shift [rad] 1.1±0.5 1.3±0.8 1.1±0.5 PN0.05
Significant differences between parameters at rest and during LBNP are
indicated in bold. (LF: low-frequency, HF: high-frequency, RRI: RR-
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